|
| 37672793 | Associations of inflammation-related proteome with demographic and clinical characteristics of people with HIV in South Africa. | Proteomics Clin Appl | 2024 |
| 37672793 | Associations of inflammation-related proteome with demographic and clinical characteristics of people with HIV in South Africa. | Proteomics Clin Appl | 2024 |
| 38051788 | The immunogenicity of an HIV-1 Gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapy. | AIDS | 2024 |
| 38051788 | The immunogenicity of an HIV-1 Gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapy. | AIDS | 2024 |
| 36354048 | Approaching the asymptote. | Lancet HIV | 2023 |
| 36354048 | Approaching the asymptote. | Lancet HIV | 2023 |
| 37949070 | Dominant CD4<sup>+</sup> TÂ cell receptors remain stable throughout antiretroviral therapy-mediated immune restoration in people with HIV. | Cell Rep Med | 2023 |
| 37738247 | Recommendations on data sharing in HIV drug resistance research. | PLoS Med | 2023 |
| 38051993 | Phase IIÂ study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19. | Future Virol | 2023 |
| 37957382 | Viral and host mediators of non-suppressible HIV-1 viremia. | Nat Med | 2023 |
| 36911658 | Highlights from the Tenth International Workshop on HIV Persistence during Therapy, December 13-16, 2022, Miami, Florida-USA. | J Virus Erad | 2023 |
| 37469618 | Food Insecurity Is Associated With Low Tenofovir Diphosphate in Dried Blood Spots in South African Persons With HIV. | Open Forum Infect Dis | 2023 |
| 37034605 | Viral and Host Mediators of Non-Suppressible HIV-1 Viremia. | medRxiv | 2023 |
| 37406137 | Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana. | Sci Transl Med | 2023 |
| 37340869 | Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure. | Clin Infect Dis | 2023 |
| 36642087 | Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. | Lancet HIV | 2023 |
| 37265259 | Broadly neutralizing antibodies and long-acting antiretroviral drugs as treatments for HIV. | Curr Opin HIV AIDS | 2023 |
| 37201510 | Immune Modulation of HIV-1 Reservoir Size in Early-Treated Neonates. | J Infect Dis | 2023 |
| 37139652 | Alternative options for treatment-experienced people with HIV. | AIDS | 2023 |
| 36729692 | Brief Report: Long-Term Clinical, Immunologic, and Virologic Outcomes Among Early-Treated Children With HIV in Botswana: A Nonrandomized Controlled Clinical Trial. | J Acquir Immune Defic Syndr | 2023 |
| 37497681 | Effect of the L74I Polymorphism on Fitness of Cabotegravir-Resistant Variants of Human Immunodeficiency Virus 1 Subtype A6. | J Infect Dis | 2023 |
| 36660823 | Long-Acting Cabotegravir and Rilpivirine: Innovation, New Challenges, and Opportunities. | Clin Infect Dis | 2023 |
| 37957382 | Viral and host mediators of non-suppressible HIV-1 viremia. | Nat Med | 2023 |
| 37949070 | Dominant CD4<sup>+</sup> TÂ cell receptors remain stable throughout antiretroviral therapy-mediated immune restoration in people with HIV. | Cell Rep Med | 2023 |
| 38051993 | Phase IIÂ study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19. | Future Virol | 2023 |
| 37738247 | Recommendations on data sharing in HIV drug resistance research. | PLoS Med | 2023 |
| 37497681 | Effect of the L74I Polymorphism on Fitness of Cabotegravir-Resistant Variants of Human Immunodeficiency Virus 1 Subtype A6. | J Infect Dis | 2023 |
| 37469618 | Food Insecurity Is Associated With Low Tenofovir Diphosphate in Dried Blood Spots in South African Persons With HIV. | Open Forum Infect Dis | 2023 |
| 37340869 | Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure. | Clin Infect Dis | 2023 |
| 37406137 | Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana. | Sci Transl Med | 2023 |
| 37139652 | Alternative options for treatment-experienced people with HIV. | AIDS | 2023 |
| 37201510 | Immune Modulation of HIV-1 Reservoir Size in Early-Treated Neonates. | J Infect Dis | 2023 |
| 37034605 | Viral and Host Mediators of Non-Suppressible HIV-1 Viremia. | medRxiv | 2023 |
| 37265259 | Broadly neutralizing antibodies and long-acting antiretroviral drugs as treatments for HIV. | Curr Opin HIV AIDS | 2023 |
| 36911658 | Highlights from the Tenth International Workshop on HIV Persistence during Therapy, December 13-16, 2022, Miami, Florida-USA. | J Virus Erad | 2023 |
| 36642087 | Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. | Lancet HIV | 2023 |
| 36729692 | Brief Report: Long-Term Clinical, Immunologic, and Virologic Outcomes Among Early-Treated Children With HIV in Botswana: A Nonrandomized Controlled Clinical Trial. | J Acquir Immune Defic Syndr | 2023 |
| 36660823 | Long-Acting Cabotegravir and Rilpivirine: Innovation, New Challenges, and Opportunities. | Clin Infect Dis | 2023 |
| 34596223 | Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort. | Clin Infect Dis | 2022 |
| 36106155 | The ethical case for placebo control in HIV-cure-related studies with ART interruption. | J Virus Erad | 2022 |
| 36094485 | Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children. | J Acquir Immune Defic Syndr | 2022 |
| 35888748 | Crosstalk between Host Genome and Metabolome among People with HIV in South Africa. | Metabolites | 2022 |
| 35567754 | Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. | Clin Pharmacol Ther | 2022 |
| 35858580 | Immune correlates of HIV-1 reservoir cell decline in early-treated infants. | Cell Rep | 2022 |
| 36410387 | Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)? | Clin Infect Dis | 2022 |
| 35293094 | Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment-limited individuals living with HIV. | HIV Med | 2022 |
| 35226530 | Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions. | Ann Intern Med | 2022 |
| 35023287 | Comparing effectiveness of first-line antiretroviral therapy between peri-urban and rural clinics in KwaZulu-Natal, South Africa. | HIV Med | 2022 |
| 34596223 | Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort. | Clin Infect Dis | 2022 |
| 35176755 | Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. | Clin Infect Dis | 2022 |